791-Targeting uPAR-Positive Tumor with CAR T Cell Therapy

Paper Talk · Apr 14, 2026 · 26m

This research identifies the urokinase plasminogen activator receptor (uPAR) as a vital target for CAR T cell therapy in solid tumors. While traditional treatments struggle with the fibrotic and immunosuppressive environment of tumors, uPAR CAR T cells effectively eliminate both malignant cells and the supportive stromal niche. These engineered cells show remarkable success in clearing primary and metastatic tumors in various preclinical models while maintaining a favorable safety profile. Furthermore, the study demonstrates that senescence-inducing therapies can increase uPAR expression…